Compare The Coca-Cola Co K (KO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Sana Biotechnology Inc — how do they compare? The Coca-Cola Co K trades at $88.18 (market cap $377.63B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: The Coca-Cola Co K is far larger — about 451.3× Sana Biotechnology Inc's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Sana Biotechnology Inc for 23 Days on average.
| KO | SANA | |
|---|---|---|
Market Cap | $377.63B | $836.71M |
Volume | 14,894,568 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $5.92 |
52-Week Low | $66.37 | $2.68 |
Typical Hold Time | 154 Days | 23 Days |
Enterprise Value | $404.81B | $749.96M |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $88.05, up 2.6% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $0.97 versus $0.92, maintaining a 61.89% gross margin and 28.56% net income margin. Recent institutional buying activity and positive analyst sentiment (60.42% buy ratings) support the stock's upward trajectory.
KO presents a compelling investment case with consistent earnings outperformance and a 64-year dividend growth streak. However, elevated valuation ratios (P/E 26.36, P/S 7.55) and regional demand divergence pose risks. The consensus price target of $95.75 suggests 8.7% upside potential from current levels, supported by strong cash flow generation and brand dominance.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
